Friday 6 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

118.74 0.73 +0.62%

Follow INCY

Alert me

Market cap: $24.1B
P/E: 56.3×
Fwd P/E: 55.6×
Dividend yield: —
F-score: 9/9
Altman Z: 8.57
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation 8-K filed Mar 30, 2026

Period ended Mar 26, 2026 · Filed Mar 30, 2026 · accepted 5:35 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Red flags

Officer departure Mar 30, 2026
Incyte Corporation reported the departure of an officer or director

8-K filed Mar 30, 2026 · The filing · sec.gov